Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)

NCT03164772 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.

NCT NCT03164772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Ludwig Institute for Cancer Research
Phase
Phase 1/2
Overall status
Completed
Start date
December 20, 2017
Completion date
October 29, 2021
Enrollment
61 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer, nsclc